" Core One Labs (CSE:COOL) receives Health Canada approval for DMT

Health Canada has authorized Core One (COOL) to add DMT to its Controlled Drugs and Substances Act Dealer’s License.

" Algernon Pharmaceuticals (CSE:AGN) completes manufacturing of DMT and appoints UK stroke experts for phase 2 trials

Algernon Pharmaceuticals (AGN) has manufactured a supply of clinical-grade AP-188 DMT for its planned phase 1 and phase 2 clinical trials.
The Market Herald Video

" Algernon (CSE:AGN) announces positive feedback on its planned Phase 1/2a DMT Human Stroke Study

Algernon (AGN) received positive feedback at a scientific advice meeting from the United Kingdom Medicines and Healthcare Products Regulatory Agency.

" PharmaDrug (CSE:PHRX) advances psychedelics program to treat eye diseases

PharmaDrug Inc. (PHRX) announced Terasaki Institute for Biomedical Innovation (TIBI) will begin in vitro studies on a short-list of DMT analogue molecules.
The Market Herald Video

" Algernon Pharmaceuticals (CSE:AGN) establishes optimum treatment period for DMT in neuron study

Algernon Pharmaceuticals (AGN) has established the optimum peak stimulation period for neuron outgrowth by AP-188 (DMT) in its pre-clinical in vitro study.
Small Pharma - Chief Medical and Scientific Officer, Carol Routledge.

" Small Pharma (TSXV:DMT) granted fast-track designation for DMT-assisted therapy

Small Pharma (DMT) has been granted fast-track designation in the U.K. for DMT-assisted therapy for major depressive disorder.

" Algernon (CSE:AGN) files meeting request with the MHRA for use of DMT in human stroke study

Algernon Pharmaceuticals (AGN) has filed a scientific advice meeting request with the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA). 

" Algernon Pharmaceuticals (CSE:AGN) confirms DMT increases neuron growth

Algernon Pharmaceuticals (AGN) has confirmed that DMT increased neuron growth by 40 per cent in a preclinical study.
Entheon Biomedical - Advisor, David Erritzoe.

" Entheon Biomedical (CSE:ENBI) appoints Dr. David Erritzoe to Advisory Board

Entheon (ENBI) has appointed David Erritzoe, Clinical Director of Imperial College’s Center for Psychedelic Research, to its Advisory Board.

" Algernon Pharmaceuticals (CSE:AGN) shares an animal study that confirms the effectiveness of DMT in treating stroke

Algernon Pharmaceuticals Inc. (AGN) is pleased to share results from an independent research study from the University of Szeged in Hungary.

" Algernon Pharmaceuticals (CSE:AGN) receives positive feedback from U.S. FDA for its DMT clinical research program

Algernon Pharmaceuticals (AGN) has received positive feedback from the FDA regarding its DMT stroke clinical research program.